This company listing is no longer active
Probiotec Résultats passés
Passé contrôle des critères 2/6
Probiotec has been growing earnings at an average annual rate of 24.6%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 24.6% per year. Probiotec's return on equity is 9.8%, and it has net margins of 3.9%.
Informations clés
24.6%
Taux de croissance des bénéfices
19.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 31.2% |
| Taux de croissance des recettes | 24.6% |
| Rendement des fonds propres | 9.8% |
| Marge nette | 3.9% |
| Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Probiotec gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 221 | 9 | 47 | 0 |
| 30 Sep 23 | 218 | 10 | 45 | 0 |
| 30 Jun 23 | 214 | 11 | 44 | 0 |
| 31 Mar 23 | 209 | 13 | 43 | 0 |
| 31 Dec 22 | 204 | 15 | 41 | 0 |
| 30 Sep 22 | 193 | 14 | 40 | 0 |
| 30 Jun 22 | 182 | 14 | 38 | 0 |
| 31 Dec 21 | 163 | 8 | 34 | 0 |
| 30 Sep 21 | 142 | 7 | 31 | 0 |
| 30 Jun 21 | 121 | 5 | 28 | 0 |
| 31 Dec 20 | 106 | 6 | 24 | 0 |
| 30 Sep 20 | 106 | 6 | 22 | 0 |
| 30 Jun 20 | 107 | 6 | 21 | 0 |
| 31 Mar 20 | 96 | 5 | 19 | 0 |
| 31 Dec 19 | 84 | 4 | 18 | 0 |
| 30 Sep 19 | 79 | 4 | 17 | 0 |
| 30 Jun 19 | 73 | 4 | 17 | 0 |
| 31 Mar 19 | 73 | 4 | 18 | 0 |
| 31 Dec 18 | 72 | 4 | 19 | 0 |
| 30 Sep 18 | 69 | 3 | 19 | 0 |
| 30 Jun 18 | 66 | 3 | 19 | 0 |
| 31 Dec 17 | 60 | 2 | 18 | 0 |
| 30 Sep 17 | 61 | 3 | 18 | 0 |
| 30 Jun 17 | 61 | 3 | 18 | 0 |
| 31 Dec 16 | 63 | 3 | 19 | 0 |
| 30 Sep 16 | 64 | 3 | 20 | 0 |
| 30 Jun 16 | 66 | 2 | 20 | 0 |
| 31 Dec 15 | 64 | 1 | 22 | 0 |
| 30 Sep 15 | 64 | 1 | 22 | 0 |
| 30 Jun 15 | 63 | 0 | 23 | 0 |
| 31 Dec 14 | 65 | -1 | 24 | 0 |
| 30 Sep 14 | 67 | 0 | 24 | 0 |
| 30 Jun 14 | 68 | 1 | 25 | 0 |
| 31 Dec 13 | 65 | 2 | 25 | 0 |
| 30 Sep 13 | 66 | 2 | 26 | 0 |
| 30 Jun 13 | 67 | 1 | 27 | 0 |
Des revenus de qualité: PBP has high quality earnings.
Augmentation de la marge bénéficiaire: PBP's current net profit margins (3.9%) are lower than last year (7.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: PBP's earnings have grown significantly by 24.6% per year over the past 5 years.
Accélération de la croissance: PBP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: PBP had negative earnings growth (-41%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16%).
Rendement des fonds propres
ROE élevé: PBP's Return on Equity (9.8%) is considered low.